Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Channing J Der

Showing results (211-220 of 236) with videos related to

Pageof 24
Sort By:
Cancer Research|February 11, 2025
Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic CancerJonathan M DeLiberty, Mallory K Roach, Clint A Stalnecker, et al.
Cancer Research|October 24, 2025
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, G Aaron Hobbs, Raven Davidson, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Cancer Discovery|November 28, 2019
Gain-of-Function <i>RHOA</i> Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric CancerHaisheng Zhang, Antje Schaefer, Yichen Wang, et al.
Cancer Research|November 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic CancerSzu-Aun Long, Haley Todd, Grace Goodhart, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Cancer Research|January 20, 2026
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor MicroenvironmentRachel A Burge, Ozgun Le Roux, Olesja Popow, et al.
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Cancer Research|November 5, 2021
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and GrowthDanielle R Cook, Melissa Kang, Timothy D Martin, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Pageof 24

Showing results (211-220 of 236) with videos related to

Sort By:
Pageof 24
Cancer Research|February 11, 2025
Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic CancerJonathan M DeLiberty, Mallory K Roach, Clint A Stalnecker, et al.
Cancer Research|October 24, 2025
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, G Aaron Hobbs, Raven Davidson, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Cancer Discovery|November 28, 2019
Gain-of-Function <i>RHOA</i> Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric CancerHaisheng Zhang, Antje Schaefer, Yichen Wang, et al.
Cancer Research|November 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic CancerSzu-Aun Long, Haley Todd, Grace Goodhart, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Cancer Research|January 20, 2026
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor MicroenvironmentRachel A Burge, Ozgun Le Roux, Olesja Popow, et al.
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Cancer Research|November 5, 2021
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and GrowthDanielle R Cook, Melissa Kang, Timothy D Martin, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Pageof 24